Evidence check: HbA1c in the context of Langlebigkeit

The provided context does not contain specific information on HbA1c in relation to longevity. From general medical knowledge, HbA1c is a well-established biomarker for average blood glucose over the past 2–3 months. Epidemiological studies indicate that HbA1c levels in the lower normal range (e.g., <5.7%) are associated with reduced cardiovascular mortality and increased healthspan. However, the evidence for a direct causal role in longevity is moderate, as HbA1c is primarily a surrogate marker for glycemic control and is influenced by factors such as age, ethnicity, and hemoglobin variants. Randomized controlled trials demonstrating that lowering HbA1c in healthy individuals extends lifespan are lacking. Thus, its predictive value for individual longevity recommendations is limited. Evidence is graded as human-moderate, based on observational studies and physiological plausibility. No sources from the context are available.